gdc

Immunotherapy

Why Does Immunotherapy Work for Some but Not for Others?
Immunotherapy
Immunotherapies expose cancer cells to the immune system so it can attack them. Read about why these drugs work so well in some patients but in others the immune system doesn’t respond to these very promising drugs.
Immunotherapy Drugs Extend Survival of Patients with Lung Cancer
ImmunotherapyLung Cancer
Check out some of the most exciting immunotherapies that are giving hope to people fighting this disease, which is responsible for 1 in every 4 cancer-related deaths in the United States.
New Immunotherapy Drugs Are Making Headway in the Treatment of Bladder Cancer
Bladder CancerImmunotherapy
Take a look at the 5 new promising immunotherapies approved by the FDA for bladder cancer after decades of no new treatment options for this type of cancer.
Immunotherapies for Patients with Lung Cancer
ImmunotherapyLung Cancer
Lung cancer is the leading cause of cancer-related deaths in the United States. According to the American Cancer Society, approximately 224,390 people will be diagnosed with lung cancer in 2016, and more than 158,000 patients will die from this disease. Smoking is the major risk factor for lung cancer–80% of lung cancer deaths are related to smoking.
Elotuzumab, First-in-Class Monoclonal Antibody Immuno­­therapy, Improves Outcomes in Patients with Multiple Myeloma
ImmunotherapyMultiple Myeloma
“This therapy is an innovative approach, one that combines the precision of a targeted, immune-based therapy with traditional myeloma therapy. The results are very encouraging, giving renewed hope to patients who have relapsed,” says ASCO President-Elect Julie M. Vose, MD, MBA, Chief of the Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha.
Page 6 of 6
Results 51 - 57 of 57

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country